常温体外肺灌注技术治疗肺缺血再灌注损伤的研究进展

Progress in the treatment of lung ischemia-reperfusion injury by ex vivo lung perfusion at normal temperature

肺移植作为终末期肺疾病的有效治疗方式,可改善患者生活质量和预后。供肺发生严重缺血再灌注损伤(IRI)会引起原发性移植物功能障碍,影响移植术后生存率。肺IRI发生的相关分子机制尚不完全清楚,因此探索IRI的发生机制,寻找其新的治疗和管理手段,对于肺移植的结局至关重要。常温体外肺灌注(EVLP)作为一种保存、评估和修复边缘肺移植物的技术,目前开展了与EVLP相关的一系列治疗肺IRI研究。本文综述肺IRI的相关机制以及EVLP期间针对肺IRI的精准化治疗,旨在为EVLP期间对供肺IRI进行特定的靶向和个性化治疗提供依据。

Lung transplantation has improved the quality of life and prognosis of patients with various end-stage lung illnesses as an efficient therapy. Severe ischemia-reperfusion injury (IRI) in the donor lung might result in primary graft dysfunction, lowering the overall survival probability following transplant.The mechanism behind the incidence of IRI is currently unknown. As a result, it is critical for the success of lung transplantation to investigate the mechanism of IRI and develop innovative methods of IRI therapy and management. A number of research on treatment IRI have been conducted as a strategy for conserving, assessing, and healing marginal lung grafts. This study outlines the main IRI processes and several IRI treatment techniques during ex vivo lung perfusion (EVLP), with the goal of providing a foundation for precise targeted and tailored therapy of lung IRI during EVLP.